ArticleGlobal health & medicine2025
Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab.
Article in Global health & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Biosimilar disease-modifying anti-rheumatic drugs offer cost-effective alternatives to originator biologics for RA treatment but remain expensive for long-term use. This prospective study investigated the clinical benefit of discontinuing CT-P13, a biosimilar of infliximab, in RA patients maintaining clinical remission or low disease activity. Five patients were enrolled from the IFX-SIRIUS STUDY I. CT-P13 was discontinued for 48 weeks, with evaluation using clinical indices, musculoskeletal ultrasound (MSUS), and serum biomarkers. Two patients experienced clinical relapse at weeks 5 and 36. The patient who relapsed at week 36 was re-administered CT-P13 and showed improved clinical outcomes without adverse events. Patients with non-clinical relapse showed no changes in disease activity scores or MSUS scores, with no notable alterations in serum cytokine levels. Over 50% of the patients maintained non-clinical relapse after CT-P13 discontinuation, and relapsed patients improved after re-administration without adverse events. This study was registered in the Japan Registry of Clinical Trials (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.